GLAXO

Glaxosmithkline Pharmaceuticals Share PriceGlaxoSmithKline Pharmaceuticals

₹1,678.15
21.05 (1.27%)
  • Advice
  • Hold
As on 02 December, 2023 | 08:09 BSE: 500660 NSE: GLAXOISIN: INE159A01016

Glaxosmithkline Pharmaceuticals Performance

Day Range

  • Low 1,669.95
  • High 1,708.00
₹ 1,678.15

52 Week Range

  • Low 1,227.00
  • High 1,727.00
₹ 1,678.15
  • Open Price1,670.00
  • Previous Close1,657.10
  • Volume215618

Start SIP in GlaxoSmithKline Pharmaceuticals

Start SIP

Glaxosmithkline Pharmaceuticals Share Price

  • Over 1 Month 19.28%
  • Over 3 Month 16.68%
  • Over 6 Month 26.44%
  • Over 1 Year 27.21%

Glaxosmithkline Pharmaceuticals Key Statistics

P/E Ratio 43.9
PEG Ratio -0.7
Market Cap Cr 28,429
Price to Book Ratio 16.3
EPS 34.6
Dividend 1.9
Relative Strength Index 68.94
Money Flow Index 78.81
MACD Signal 40.09
Average True Range 53.21

Glaxosmithkline Pharmaceuticals Investment Rating

  • Master Rating:
  • Glaxosmithkline Pharms. has an operating revenue of Rs. 3,308.40 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 26% is great, ROE of 35% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 18% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

GlaxoSmithKline Pharmaceuticals Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 953738782799906729792
Operating Expenses Qtr Cr 667597615571649582619
Operating Profit Qtr Cr 287141167228257148173
Depreciation Qtr Cr 18161716161615
Interest Qtr Cr 0010010
Tax Qtr Cr 814856606944262
Net Profit Qtr Cr 2161311311641941191,218
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 3,3183,294
Operating Expenses Annual Cr 2,4172,462
Operating Profit Annual in Cr 799756
Depreciation Cr 6668
Interest Annual Cr 22
Tax Annual Cr 228397
Net Profit Annual Cr 6081,691
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 488820
Cash from Investing Activity Annual Cr 805-420
Cash from Financing Annual Activity Cr -1,544-524
Net Cash Flow Annual Cr -251-124
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 1,7532,678
Fixed Assets Annual Cr 350361
Total Non Current Assets Annual Cr 861952
Total Current Assets Annual Cr 2,4673,671
Total Assets Annual Cr 3,3284,623
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 103158
ROE Annual % 3563
ROCE Annual % 4226
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2826
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 957762787802917745810
Operating Expenses Qtr Cr 668618618574660596634
Operating Profit Qtr Cr 289144170229257149175
Depreciation Qtr Cr 18161716161615
Interest Qtr Cr 0010010
Tax Qtr Cr 824957606944263
Net Profit Qtr Cr 2181321331651931191,219
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 3,3523,354
Operating Expenses Annual Cr 2,4472,516
Operating Profit Annual in Cr 804762
Depreciation Cr 6668
Interest Annual Cr 22
Tax Annual Cr 229398
Net Profit Annual Cr 6171,695
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 484811
Cash from Investing Activity Annual Cr 808-406
Cash from Financing Annual Activity Cr -1,543-524
Net Cash Flow Annual Cr -251-119
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 1,7412,663
Fixed Assets Annual Cr 350361
Total Non Current Assets Annual Cr 832925
Total Current Assets Annual Cr 2,4943,708
Total Assets Annual Cr 3,3274,633
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 103157
ROE Annual % 3564
ROCE Annual % 4226
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2826

Glaxosmithkline Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,678.15
21.05 (1.27%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹1,591.13
  • 50 Day
  • ₹1,535.75
  • 100 Day
  • ₹1,488.82
  • 200 Day
  • ₹1,443.36
  • 20 Day
  • ₹1,561.96
  • 50 Day
  • ₹1,531.48
  • 100 Day
  • ₹1,479.28
  • 200 Day
  • ₹1,396.05

Glaxosmithkline Pharmaceuticals Resistance and Support

PIVOT
₹1,685.37
Resistance
First Resistance 1,700.78
Second Resistance 1,723.42
Third Resistance 1,738.83
RSI 68.94
MFI 78.81
MACD Single Line 40.09
MACD 50.42
Support
First Resistance 1,662.73
Second Resistance 1,647.32
Third Resistance 1,624.68

Glaxosmithkline Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 222,103 13,905,869 62.61
Week 206,419 12,562,660 60.86
1 Month 222,897 14,071,494 63.13
6 Month 107,714 7,042,354 65.38

Glaxosmithkline Pharmaceuticals Result Highlights

GlaxoSmithKline Pharmaceuticals Synopsis

NSE-Medical-Diversified

Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3216.34 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2023. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.
Market Cap 28,429
Sales 3,273
Shares in Float 4.24
No of funds 196
Yield 1.91
Book Value 16.22
U/D Vol ratio 1.3
LTDebt / Equity
Alpha 0.08
Beta 0.34

GlaxoSmithKline Pharmaceuticals

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 75%75%75%75%
Mutual Funds 4.81%4.25%3.96%4.12%
Insurance Companies 5.15%5.97%6.29%6.1%
Foreign Portfolio Investors 2.5%2.41%2.28%2.28%
Financial Institutions/ Banks 0.01%0.01%0.01%0.01%
Individual Investors 10.62%10.57%10.54%10.56%
Others 1.91%1.79%1.92%1.93%

GlaxoSmithKline Pharmaceuticals Management

Name Designation
Ms. R S Karnad Chairperson
Mr. B Akshikar Managing Director
Dr.(Ms.) S Maheshwari Director
Mr. S Williams Director
Mr. P V Bhide Director
Mr. A N Roy Director
Mr. D Sundaram Director
Mr. M Anand Director
Mr. J Chandy Director

Glaxosmithkline Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glaxosmithkline Pharmaceuticals Corporate Action

Date Purpose Remarks
2023-11-09 Quarterly Results
2023-07-26 Quarterly Results
2023-05-17 Audited Results & Final Dividend
2023-02-07 Quarterly Results
2022-11-11 Quarterly Results
Date Purpose Remarks
2023-06-30 FINAL Rs.32.00 per share(320%)Final Dividend
2022-07-08 FINAL Rs.30.00 per share(300%)Dividend
2022-07-08 SPECIAL Rs.60.00 per share(600%)Special Dividend
2021-07-20 FINAL Rs.30.00 per share(300%)Dividend

GlaxoSmithKline Pharmaceuticals MF Shareholding

Name Amount(cr)
ICICI Prudential Bluechip Fund Growth 41,269
Nippon India Small Cap Fund - Growth 37,319
ICICI Prudential Value Discovery Fund Growth 32,494
ICICI Prudential Multi-Asset Fund Growth 24,931
Nippon India Growth Fund - Growth 19,082

GlaxoSmithKline Pharmaceuticals FAQs

What is Share Price of GlaxoSmithKline Pharmaceuticals ?

GlaxoSmithKline Pharmaceuticals share price is ₹1,678 As on 02 December, 2023 | 07:55

What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?

The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹28428.9 Cr As on 02 December, 2023 | 07:55

What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?

The P/E ratio of GlaxoSmithKline Pharmaceuticals is 43.9 As on 02 December, 2023 | 07:55

What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?

The PB ratio of GlaxoSmithKline Pharmaceuticals is 16.3 As on 02 December, 2023 | 07:55

Q2FY23